ADMA Biologics Inc
ADMA19.280USD
-0.260-1.33%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
4.60BMarket Cap
21.72P/E TTM
More Details of ADMA Biologics Inc Company
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
ADMA Biologics Inc Info
Ticker SymbolADMA
Company nameADMA Biologics Inc
IPO dateOct 17, 2013
CEOGrossman (Adam S)
Number of employees677
Security typeOrdinary Share
Fiscal year-endOct 17
Address465 State Route 17
CityRAMSEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07446
Phone12014785552
Websitehttps://www.admabiologics.com/
Ticker SymbolADMA
IPO dateOct 17, 2013
CEOGrossman (Adam S)
Company Executives of ADMA Biologics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.74M
-0.16%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
570.90K
--
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
258.17K
-2.68%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
145.83K
-12.06%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
--
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
--
Dr. Young T. Kwon, Ph.D.
Dr. Young T. Kwon, Ph.D.
Independent Director
Independent Director
--
--
Ms. Alison C. Finger
Ms. Alison C. Finger
Independent Director
Independent Director
--
--
Ms. Kaitlin Kestenberg
Ms. Kaitlin Kestenberg
Chief Operating Officer, Senior Vice President - Compliance
Chief Operating Officer, Senior Vice President - Compliance
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.74M
-0.16%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
570.90K
--
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
258.17K
-2.68%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
145.83K
-12.06%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
--
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
121.98M
0.00%
International
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 30
Updated: Sun, Nov 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.74%
The Vanguard Group, Inc.
8.79%
State Street Investment Management (US)
5.70%
Invesco Advisers, Inc.
4.41%
Sachem Head Capital Management LP
3.76%
Other
63.60%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.74%
The Vanguard Group, Inc.
8.79%
State Street Investment Management (US)
5.70%
Invesco Advisers, Inc.
4.41%
Sachem Head Capital Management LP
3.76%
Other
63.60%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.50%
Investment Advisor/Hedge Fund
30.59%
Hedge Fund
11.30%
Research Firm
2.64%
Individual Investor
2.56%
Private Equity
1.42%
Pension Fund
1.25%
Bank and Trust
0.72%
Venture Capital
0.32%
Other
2.69%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
739
228.97M
97.85%
+101.59K
2025Q3
751
228.86M
99.47%
+11.41M
2025Q2
715
217.50M
96.72%
+4.57M
2025Q1
648
212.83M
94.42%
-12.40M
2024Q4
604
209.18M
96.94%
-6.58M
2024Q3
539
214.99M
86.57%
+25.19M
2024Q2
441
187.54M
84.10%
+4.18M
2024Q1
399
182.51M
80.76%
-4.67M
2023Q4
363
176.61M
82.02%
-3.09M
2023Q3
353
180.50M
79.57%
+5.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
33.35M
13.98%
-846.07K
-2.47%
Jun 30, 2025
The Vanguard Group, Inc.
21.31M
8.93%
+4.52M
+26.94%
Jun 30, 2025
State Street Investment Management (US)
12.08M
5.06%
+637.73K
+5.57%
Jun 30, 2025
Invesco Advisers, Inc.
10.20M
4.27%
+508.12K
+5.24%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.91M
2.48%
+245.31K
+4.33%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.76M
2%
-97.24K
-2.00%
Jun 30, 2025
American Century Investment Management, Inc.
4.61M
1.93%
+358.63K
+8.43%
Jun 30, 2025
Thrivent Asset Management, LLC
3.32M
1.39%
+1.45M
+78.10%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Motley Fool Small-Cap Growth ETF
2.48%
Invesco S&P SmallCap Health Care ETF
2.26%
Harbor Health Care ETF
2.04%
State Street SPDR S&P Biotech ETF
1.35%
AAM Sawgrass US Small Cap Quality Growth ETF
1.17%
Virtus LifeSci Biotech Products ETF
1.15%
Invesco S&P SmallCap Quality ETF
1.12%
Invesco S&P SmallCap 600 Pure Growth ETF
1.05%
Invesco S&P SmallCap 600 GARP ETF
1.05%
Invesco S&P SmallCap Momentum ETF
0.83%
View more
Motley Fool Small-Cap Growth ETF
Proportion2.48%
Invesco S&P SmallCap Health Care ETF
Proportion2.26%
Harbor Health Care ETF
Proportion2.04%
State Street SPDR S&P Biotech ETF
Proportion1.35%
AAM Sawgrass US Small Cap Quality Growth ETF
Proportion1.17%
Virtus LifeSci Biotech Products ETF
Proportion1.15%
Invesco S&P SmallCap Quality ETF
Proportion1.12%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.05%
Invesco S&P SmallCap 600 GARP ETF
Proportion1.05%
Invesco S&P SmallCap Momentum ETF
Proportion0.83%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ADMA Biologics Inc?
The top five shareholders of ADMA Biologics Inc are:
BlackRock Institutional Trust Company, N.A. holds 33.35M shares, accounting for 13.98% of the total shares.
The Vanguard Group, Inc. holds 21.31M shares, accounting for 8.93% of the total shares.
State Street Investment Management (US) holds 12.08M shares, accounting for 5.06% of the total shares.
Invesco Advisers, Inc. holds 10.20M shares, accounting for 4.27% of the total shares.
Geode Capital Management, L.L.C. holds 5.91M shares, accounting for 2.48% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 33.35M shares, accounting for 13.98% of the total shares.
The Vanguard Group, Inc. holds 21.31M shares, accounting for 8.93% of the total shares.
State Street Investment Management (US) holds 12.08M shares, accounting for 5.06% of the total shares.
Invesco Advisers, Inc. holds 10.20M shares, accounting for 4.27% of the total shares.
Geode Capital Management, L.L.C. holds 5.91M shares, accounting for 2.48% of the total shares.
What are the top three shareholder types of ADMA Biologics Inc?
The top three shareholder types of ADMA Biologics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
How many institutions hold shares of ADMA Biologics Inc (ADMA)?
As of 2025Q4, 739 institutions hold shares of ADMA Biologics Inc, with a combined market value of approximately 228.97M, accounting for 97.85% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.62%.
What is the biggest source of revenue for ADMA Biologics Inc?
In FY2025Q2, the -- business generated the highest revenue for ADMA Biologics Inc, amounting to -- and accounting for --% of total revenue.
